Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice

Takayuki Kondo, Misato Funayama, Kayoko Tsukita, Akitsu Hotta, Akimasa Yasuda, Satoshi Nori, Shinjiro Kaneko, Masaya Nakamura, Ryosuke Takahashi, Hideyuki Okano, Shinya Yamanaka, Haruhisa Inoue

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Transplantation of glial-rich neural progenitors has been demonstrated to attenuate motor neuron degeneration and disease progression in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these results into a clinical setting requires a renewable human cell source. Here, we derived glial-rich neural progenitors from human iPSCs and transplanted them into the lumbar spinal cord of ALS mouse models. The transplanted cells differentiated into astrocytes, and the treated mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source.

Original languageEnglish
Pages (from-to)242-249
Number of pages8
JournalStem Cell Reports
Volume3
Issue number2
DOIs
Publication statusPublished - 2014 Aug 12

Fingerprint

Amyotrophic Lateral Sclerosis
Neuroglia
Transplantation
Spinal Cord
Neurons
Superoxide Dismutase
Nerve Degeneration
Motor Neuron Disease
Chemical activation
Cells
Cell- and Tissue-Based Therapy
Astrocytes
Disease Progression
Rodentia
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Developmental Biology
  • Genetics
  • Medicine(all)

Cite this

Kondo, T., Funayama, M., Tsukita, K., Hotta, A., Yasuda, A., Nori, S., ... Inoue, H. (2014). Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports, 3(2), 242-249. https://doi.org/10.1016/j.stemcr.2014.05.017

Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. / Kondo, Takayuki; Funayama, Misato; Tsukita, Kayoko; Hotta, Akitsu; Yasuda, Akimasa; Nori, Satoshi; Kaneko, Shinjiro; Nakamura, Masaya; Takahashi, Ryosuke; Okano, Hideyuki; Yamanaka, Shinya; Inoue, Haruhisa.

In: Stem Cell Reports, Vol. 3, No. 2, 12.08.2014, p. 242-249.

Research output: Contribution to journalArticle

Kondo, T, Funayama, M, Tsukita, K, Hotta, A, Yasuda, A, Nori, S, Kaneko, S, Nakamura, M, Takahashi, R, Okano, H, Yamanaka, S & Inoue, H 2014, 'Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice', Stem Cell Reports, vol. 3, no. 2, pp. 242-249. https://doi.org/10.1016/j.stemcr.2014.05.017
Kondo, Takayuki ; Funayama, Misato ; Tsukita, Kayoko ; Hotta, Akitsu ; Yasuda, Akimasa ; Nori, Satoshi ; Kaneko, Shinjiro ; Nakamura, Masaya ; Takahashi, Ryosuke ; Okano, Hideyuki ; Yamanaka, Shinya ; Inoue, Haruhisa. / Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. In: Stem Cell Reports. 2014 ; Vol. 3, No. 2. pp. 242-249.
@article{ce1bd8c6740e461380d23645a1860b4a,
title = "Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice",
abstract = "Transplantation of glial-rich neural progenitors has been demonstrated to attenuate motor neuron degeneration and disease progression in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these results into a clinical setting requires a renewable human cell source. Here, we derived glial-rich neural progenitors from human iPSCs and transplanted them into the lumbar spinal cord of ALS mouse models. The transplanted cells differentiated into astrocytes, and the treated mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source.",
author = "Takayuki Kondo and Misato Funayama and Kayoko Tsukita and Akitsu Hotta and Akimasa Yasuda and Satoshi Nori and Shinjiro Kaneko and Masaya Nakamura and Ryosuke Takahashi and Hideyuki Okano and Shinya Yamanaka and Haruhisa Inoue",
year = "2014",
month = "8",
day = "12",
doi = "10.1016/j.stemcr.2014.05.017",
language = "English",
volume = "3",
pages = "242--249",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice

AU - Kondo, Takayuki

AU - Funayama, Misato

AU - Tsukita, Kayoko

AU - Hotta, Akitsu

AU - Yasuda, Akimasa

AU - Nori, Satoshi

AU - Kaneko, Shinjiro

AU - Nakamura, Masaya

AU - Takahashi, Ryosuke

AU - Okano, Hideyuki

AU - Yamanaka, Shinya

AU - Inoue, Haruhisa

PY - 2014/8/12

Y1 - 2014/8/12

N2 - Transplantation of glial-rich neural progenitors has been demonstrated to attenuate motor neuron degeneration and disease progression in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these results into a clinical setting requires a renewable human cell source. Here, we derived glial-rich neural progenitors from human iPSCs and transplanted them into the lumbar spinal cord of ALS mouse models. The transplanted cells differentiated into astrocytes, and the treated mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source.

AB - Transplantation of glial-rich neural progenitors has been demonstrated to attenuate motor neuron degeneration and disease progression in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these results into a clinical setting requires a renewable human cell source. Here, we derived glial-rich neural progenitors from human iPSCs and transplanted them into the lumbar spinal cord of ALS mouse models. The transplanted cells differentiated into astrocytes, and the treated mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source.

UR - http://www.scopus.com/inward/record.url?scp=84924219720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924219720&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2014.05.017

DO - 10.1016/j.stemcr.2014.05.017

M3 - Article

VL - 3

SP - 242

EP - 249

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 2

ER -